Loading
Life sciences · Journal article
Biology Direct · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Renal cell carcinoma (RCC) is the most common urological malignancy, with its global incidence having increased substantially in recent years. The limited efficacy of conventional therapies, including chemotherapy and radiotherapy, contributes to poor clinical outcomes, highlighting the need for a better understanding of the molecular mechanisms underlying RCC progression and treatment resistance. Such insights may facilitate improved patient stratification and the identification of novel therapeutic targets. Here, we identified serine hydroxymethyltransferase 2 (SHMT2) as a key metabolic enzyme involved in cancer-associated metabolic reprogramming and RCC cell proliferation. SHMT2 expression was significantly higher in RCC tissues than in their normal counterparts, and its overexpression was associated with poorer patient prognosis. Pharmacological inhibition of SHMT activity significantly reduced RCC cell proliferation and was accompanied by activation of the autophagic pathway. Furthermore, SHMT inhibition increased reactive oxygen species (ROS) production and markedly decreased mitochondrial spare respiratory capacity in ACHN cells. Notably, pharmacological inhibition of SHMTs sensitized RCC cell lines to the tyrosine kinase inhibitor sorafenib. Collectively, these findings highlight the role of SHMT2 in RCC metabolism and cell survival and suggest that pharmacological inhibition of SHMTs may represent a potential therapeutic strategy for RCC. Moreover, targeting SHMT activity may offer a promising approach to sensitize RCC to the TKIs and therefore, improving the efficacy of targeted therapies.